Erythropoietin Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

The report on the global erythropoietin drugs market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global erythropoietin drugs market to grow with a CAGR of 10.2% over the forecast period from 2019-2025. The study on erythropoietin drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on erythropoietin drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global erythropoietin drugs market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global erythropoietin drugs market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

• An increasing number of patients suffering from anemic condition induced due to cancer, HIV and end-stage renal disease (ESRD)
• Presence of large patient populations
• Patent expiration of biologics

2) Restraints

• The high cost of EPO drugs

3) Opportunities

• Patent expiration of major biologics during the coming years

Research Methodology

A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global erythropoietin drugs market is segmented on the basis of drug class, product, and applications.

The Global Erythropoietin Drugs Market by Drug Class

• Biologics
• Biosimilars

The Global Erythropoietin Drugs Market by Product

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Other Products

The Global Erythropoietin Drugs Market by Applications

• Cancer
• Hematology
• Renal Diseases
• Neurology

Company Profiles

The companies covered in the report include

• Hospira Inc.
• Johnson & Johnson
• Amgen Inc.
• Roche Holding AG
• LG Life Sciences Ltd.
• Biocon Limited
• Celltrion, Inc.
• Intas Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Ranbaxy Laboratories Ltd.
• Other companies

What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the erythropoietin drugs market.
2. Complete coverage of all the segments in the erythropoietin drugs market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global erythropoietin drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.